PSMA2 Promotes Chemo- and Radioresistance of Oral Squamous Cell Carcinoma by Modulating Mitophagy Pathway

Overview

Journal Cell Death Discov

Date 2025 Jan 10

PMID 39794329

Authors

Chun-I Wang

Cheng-Yi Chen

Ting-Wen Chen

Chun-Chia Cheng

Shu-Wen Hong

Tsung-You Tsai

Kai-Ping Chang

Affiliations

Soon will be listed here.

Abstract

Oral cavity squamous cell carcinoma (OSCC) represents the most prevalent malignancy among head and neck squamous cell carcinomas (HNSCCs). Standard treatment modalities include surgical resection combined with radiation and chemotherapy. However, locoregional failure remains a critical issue affecting the prognosis of OSCC patients, largely due to tumor resistance against radiation or chemotherapy. In this study, we established a gene database related to OSCC recurrence and identified PSMA2 as a novel molecule influencing prognosis in OSCC patients. An independent Taiwanese cohort confirmed that elevated PSMA2 transcript levels were associated with poorer prognosis and contributed to the chemo- and radioresistance phenotype in OSCC. Furthermore, we confirmed that PSMA2 regulates cell cycle, mitochondrial dysfunction, and mitophagy, thereby contributing to carcinogenesis and resistance. Notably, mitophagy inducer exhibit antitumor effects in PSMA2-overexpressing OSCC xenograft mouse model. Collectively, our results provide a mechanistic understanding of the atypical function of PSMA2 in promoting OSCC recurrence.

References

Matsukawa S, Morita K, Negishi A, Harada H, Nakajima Y, Shimamoto H . Galectin-7 as a potential predictive marker of chemo- and/or radio-therapy resistance in oral squamous cell carcinoma. Cancer Med. 2014; 3(2):349-61. PMC: 3987084. DOI: 10.1002/cam4.195. View

Panigrahi D, Praharaj P, Behera B, Patra S, Patil S, Patro B . The inner mitochondrial membrane fission protein MTP18 serves as a mitophagy receptor to prevent apoptosis in oral cancer. J Cell Sci. 2023; 136(13). DOI: 10.1242/jcs.259986. View

Yan C, Li T . Dual Role of Mitophagy in Cancer Drug Resistance. Anticancer Res. 2018; 38(2):617-621. DOI: 10.21873/anticanres.12266. View

Deshmukh F, Yaffe D, Olshina M, Ben-Nissan G, Sharon M . The Contribution of the 20S Proteasome to Proteostasis. Biomolecules. 2019; 9(5). PMC: 6571867. DOI: 10.3390/biom9050190. View

Chen Q, Zheng W, Zhu L, Liu H, Song Y, Hu S . LACTB2 renders radioresistance by activating PINK1/Parkin-dependent mitophagy in nasopharyngeal carcinoma. Cancer Lett. 2021; 518:127-139. DOI: 10.1016/j.canlet.2021.07.019. View

Almond J, Cohen G . The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002; 16(4):433-43. DOI: 10.1038/sj.leu.2402417. View

Huang C, Zhang L, Ma S, Zhao Z, Wang W, He K . Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma. PLoS One. 2014; 8(12):e83479. PMC: 3873935. DOI: 10.1371/journal.pone.0083479. View

Mundekkad D, Cho W . Mitophagy Induced by Metal Nanoparticles for Cancer Treatment. Pharmaceutics. 2022; 14(11). PMC: 9699542. DOI: 10.3390/pharmaceutics14112275. View

Farah C . Narrow Band Imaging-guided resection of oral cavity cancer decreases local recurrence and increases survival. Oral Dis. 2018; 24(1-2):89-97. DOI: 10.1111/odi.12745. View

10.

Zhang Y, Xiang Z, Chen L, Deng X, Liu H, Peng X . PSMA2 promotes glioma proliferation and migration via EMT. Pathol Res Pract. 2024; 256:155278. DOI: 10.1016/j.prp.2024.155278. View

11.

Noh J, Woo S, Yun M, Lee M, Kong M, Min S . SOD2- and NRF2-associated Gene Signature to Predict Radioresistance in Head and Neck Cancer. Cancer Genomics Proteomics. 2021; 18(5):675-684. PMC: 8441763. DOI: 10.21873/cgp.20289. View

12.

Schofield J, Schafer Z . Mitochondrial Reactive Oxygen Species and Mitophagy: A Complex and Nuanced Relationship. Antioxid Redox Signal. 2020; 34(7):517-530. DOI: 10.1089/ars.2020.8058. View

13.

Liu Z, He Q, Ding X, Zhao T, Zhao L, Wang A . SOD2 is a C-myc target gene that promotes the migration and invasion of tongue squamous cell carcinoma involving cancer stem-like cells. Int J Biochem Cell Biol. 2015; 60:139-46. DOI: 10.1016/j.biocel.2014.12.022. View

14.

Wang N . Analysis of prognostic biomarker models and immune microenvironment in acute myeloid leukemia by integrative bioinformatics. J Cancer Res Clin Oncol. 2023; 149(12):9609-9619. DOI: 10.1007/s00432-023-04871-3. View

15.

Guan Y, Wang Y, Li B, Shen K, Li Q, Ni Y . Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics. Cancer Cell Int. 2021; 21(1):350. PMC: 8256582. DOI: 10.1186/s12935-021-02065-w. View

16.

Chiao C, Liu Y, Phan N, An Ton N, Ta H, Anuraga G . Prognostic and Genomic Analysis of Proteasome 20S Subunit Alpha (PSMA) Family Members in Breast Cancer. Diagnostics (Basel). 2021; 11(12). PMC: 8699889. DOI: 10.3390/diagnostics11122220. View

17.

Giotakis J, Gomatos I, Alevizos L, Georgiou A, Leandros E, Konstadoulakis M . Bax, cytochrome c, and caspase-8 staining in parotid cancer patients: markers of susceptibility in radiotherapy?. Otolaryngol Head Neck Surg. 2010; 142(4):605-11. DOI: 10.1016/j.otohns.2009.12.027. View

18.

Zhu K, Ma J, Tian Y, Liu Q, Zhang J . An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer. BMC Womens Health. 2024; 24(1):49. PMC: 10795461. DOI: 10.1186/s12905-024-02881-y. View

19.

Hosni A, Chiu K, Huang S, Xu W, Huang J, Bayley A . Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiother Oncol. 2020; 154:70-75. PMC: 7453211. DOI: 10.1016/j.radonc.2020.08.013. View

20.

Huang S, OSullivan B . Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013; 18(2):e233-40. PMC: 3613874. DOI: 10.4317/medoral.18772. View